Human CD4+ T-cell Epitope-based Therapeutic For Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$403,121.00
Summary
Peanut allergy affects ~2% of the population and peanuts are the major cause of fatal food-induced anaphylaxis. Peanut allergy usually appears in infancy and persists indefinitely. At present, unlike grass pollen allergy, there is no preventative treatment. Using blood cells from peanut-allergic patients, we will identify the components of major peanut allergens to use in _allergy shots� to develop tolerance on peanut exposure without risking anaphylaxis.
Methylation-sensitive T Cell Genes And Childhood Food Allergy.
Funder
National Health and Medical Research Council
Funding Amount
$461,232.00
Summary
Australia has the highest reported prevalence food allergy in the world. Despite this, little is known about how allergy develops. Mounting evidence implicates environmentally induced disruption of the genetic blueprint via a process known as epigenetics. We are combining the strengths of food challenge proven food allergy with assessment of immune functioning & cutting edge genomics, to extensively characterise the pathways leading to food allergy in children.
Phase I/IIa Trials Of A Novel T-cell Epitope-based Peptide Therapy For Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,440,000.00
Summary
Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.
Tissue Specific T Cells Mediate Drug Hypersensitivity
Funder
National Health and Medical Research Council
Funding Amount
$1,253,980.00
Summary
T cells are immune cells that create dangerous and fatal drug allergies affecting the skin. An individual’s genetic makeup only partially explains predisposition to these reactions, we believe the missing link is contained in immune signatures specific to the skin. We aim to identify drug-specific T cells in the skin and develop a sensitive test to screen for rare, dangerous T cells in the blood. This will enable prediction and prevention of severe drug allergy and development of safer drugs.
THE INTERFACE BETWEEN INNATE AND ADAPTIVE IMMUNITY
Funder
National Health and Medical Research Council
Funding Amount
$4,905,420.00
Summary
Allergic disorders including asthma are amongst the most prevalent diseases in Australia afflicting up to 25% of the population and costing the Australian Government in excess of $600 million annually. This program aims to understand the molecular and cellular mechanisms controlling airway inflammation, focusing on the cross-talk between scavenger cells at airway surfaces and circulating cells of the immune system. These studies will combine sophisticated mouse models of airway inflammation in t ....Allergic disorders including asthma are amongst the most prevalent diseases in Australia afflicting up to 25% of the population and costing the Australian Government in excess of $600 million annually. This program aims to understand the molecular and cellular mechanisms controlling airway inflammation, focusing on the cross-talk between scavenger cells at airway surfaces and circulating cells of the immune system. These studies will combine sophisticated mouse models of airway inflammation in the laboratory with clinical investigation and analysis of human tissue. Understanding these processes will translate into better treatments for patients suffering from life-threatening allergy and asthma.Read moreRead less
Dissecting the physiology of multipotent mesenchymal stromal cells to develop vaccine candidates for respiratory disease. The project aims to gain an understanding of how a type of adult stem cell inhibits immune responses that cause asthma. The project will produce new stem cell products and facilitate the design of a vaccine for asthma and other respiratory diseases, which would greatly reduce the burden of such conditions.